Avingtrans completes minority £2.5m investment in emerging medtech leader, Adaptix

Avingtrans PLC (LON:AVG), which designs, manufactures and supplies critical components, modules, systems and associated services to the energy, medical and industrial sectors, has announced its £2.5m participation in a £12.9m fund raise by emerging medtech leader, Adaptix Ltd, based in Oxford, UK.

Adaptix’s focus is on transforming radiology, by allowing low-cost, low-dose 3D portable imaging.  It has developed a number of novel technologies and imaging approaches in relation to Digital Tomosynthesis.  At the core of Adaptix’s technology is the ‘Flat Panel X-ray Source’ which consists of a monoblock containing an array of individually controlled X-ray emitters combined with a high-voltage power supply.

In its latest round of funding, Adaptix is raising up to a total of £12.9m of new funds, including £2.5m in cash from Avingtrans.  In return for the investment, Avingtrans will own approximately 5.9% of the total issued share capital of Adaptix, post the closing of the fund raise.

Avingtrans, through its majority owned-subsidiary Magnetica (“MNA”), intends to collaborate with Adaptix, to develop a disruptive business offering.  This offering will bring together low-cost 3D imaging in the form of MNA’s Cryogen-free MRI and Adaptix’s DT, to allow fusing of the image data, giving enhanced low-cost diagnostic capability, initially for orthopaedic imaging.  The target markets include some 28,000 US sites focused on minor injuries (urgent care) and private orthopaedic practices (private practices and ambulatory surgical centres). 

The purpose of the collaboration is  to create a broader offering to customers than is delivered by each business alone and ultimately to bring together low-cost 3D MRI, X-ray and potentially ultrasound, in a solution which can address a significant proportion of all medical and veterinary imaging procedures.

In the year to 31 March 2020, Adaptix made a loss after tax of £0.8m.

Mark Evans, CEO of Adaptix, said: “Our vision is to offer multi-modal 3D imaging to under-served medical markets in major economies focused on extremity imaging, which will be driven by a ‘Pay-per-Study’ business model.  Our competitive advantage will be facilitated by: the low cost of the equipment, protected and enabled by proprietary technology; equipment that does not need high-cost rooms and installation; and portability that enables equipment to be cheaply redeployed and therefore, facilitates new service models. We believe that by working with Avingtrans and Magnetica, we will be able to deliver a unique proposition to the medical imaging market.”     

Steve McQuillan, CEO of Avingtrans, commented: “We are excited by the prospect of Magnetica working with the team at Adaptix, to our mutual benefit.  As fellow travellers on parallel disruptive medical imaging paths, we believe that working together will deliver cost and market synergies for both businesses to enhance potential shareholder value, through better quality and flexible multi-modal imaging, enhancing the end customer experience.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Share on facebook
    Facebook
    Share on twitter
    Twitter
    Share on linkedin
    LinkedIn
    Avingtrans

    More articles like this

    Avingtrans

    Avingtrans deliver solid results and a confident outlook (VIDEO)

    Avingtrans PLC (LON:AVG) CEO Steve McQuillan joins DirectorsTalk Interviews to discuss its results for the year ended 31st May 2022. Steve talks us through the highlights, the performance and highlights in the Energy division, involvement in the Medical division,

    Avingtrans

    Avingtrans revenue from continuing operations increased by 1.9% to £100.4m

    Avingtrans PLC (LON:AVG), which designs, manufactures and supplies critical components, modules, systems and associated services to the energy, medical and industrial sectors, has announced its preliminary results for the year ended 31 May 2022. Financial Highlights ·      Revenue from

    Avingtrans

    Avingtrans’ Hayward Tyler awarded $7m nuclear contracts

    Avingtrans PLC (LON:AVG), which designs, manufactures and supplies critical components, modules, systems and associated services to the energy, medical and industrial sectors, has announced Hayward Tyler, Inc has secured two new nuclear contracts worth a total of US

    Avingtrans

    Avingtrans results, visibility and M&A opportunities (Interview)

    Avingtrans PLC (LON:AVG) CEO Steve McQuillan joins DirectorsTalk Interviews to discuss its interim results for the six months ended 30 November 2021. Steve talks us through the highlights, its strong order book, updates us on the developments with Hayward

    Avingtrans

    Avingtrans’ PIE strategy continues to deliver robust results

    Avingtrans PLC (LON:AVG), the international engineering group which designs, manufactures and supplies original equipment, systems and associated aftermarket services to the energy, medical and industrial sectors, has announced its interim results for the six months ended 30 November

    Avingtrans

    Avingtrans appoints Jo Reedman as an independent Non-Executive Director

    Avingtrans PLC (LON:AVG), which designs, manufactures and supplies critical components, modules, systems and associated services to the energy, medical and industrial sectors, has announced the appointment of Jo Reedman, as an independent Non-Executive Director, effective on 1st March 2022.

    Avingtrans

    Booth welcomes HS2 CEO for site visit

    Booth Industries was delighted to welcome HS2 CEO Mark Thurston yesterday, to view its new purpose-built facility for the manufacture of safety doors for HS2 tunnels and meet staff working on the project. The £36.5million 10-year contract was

    Avingtrans

    Avingtrans acquisition of Transkem a great strategic fit (Interview)

    Avingtrans plc (LON:AVG) PSRE Divisional Managing Director Austen Adams joins DirectorsTalk Interviews to discuss the acquisition of Hillington-based Transkem. Austen explains what the company does, how much it cost, the strategic fit with Avingtrans and if the company

    Avingtrans

    Avingtrans Pinpoint-Invest-Exit Strategy proves its worth (Interview)

    Avingtrans PLC (LON:AVG) CEO Steve McQuillan joins DirectorsTalk Interviews to discuss results for the year ended 31st May 2021. Steve talks us through the highlights, explains the Pinpoint-Invest-Exit strategy, the record order book for Booth, what planning permission

    Avingtrans

    Avingtrans record adjusted profits and a solid cash position

    Avingtrans PLC (LON:AVG), which designs, manufactures and supplies critical components, modules, systems and associated services to the energy, medical and industrial sectors, has announced its preliminary results for the year ended 31 May 2021. Financial Highlights • Revenue from